This activity expired on May 18, 2024; credit is no longer available.

Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management

Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.

Target Audience

This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
• Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
• Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina

Patrick A. Flume, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck & Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.

Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado

Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Susan Palmer

Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Insmed.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 18, 2024; credit is no longer available.

Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management

Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.

Target Audience

This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
• Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
• Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina

Patrick A. Flume, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck & Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.

Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado

Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Susan Palmer

Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Insmed.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 28, 2024; credit is no longer available.

Meeting Patient Needs Through Optimal Nursing Strategies in Personalized Bladder Cancer Care

Media: Enduring Material
Activity Release Date: April 29, 2023
Activity Expiration Date: May 28, 2024
Time to Complete Activity: 75 minutes

Activity Description

The therapeutic landscape for bladder cancer has rapidly evolved. The largely chemotherapy-based approaches of the past are giving way to the use of immune checkpoint inhibitors, targeted agents, and antibody–drug conjugates in advanced disease, as well as bladder-sparing and perioperative approaches in early-stage disease settings. How can oncology nurses synthesize the diverse body of clinical evidence on approved and emerging strategies into the realities of real-world cancer care to successfully address the therapeutic and educational needs of patients across the disease continuum?

To help nurses rise to the challenge of modern bladder cancer management, this PeerView activity, based on a recent live event and developed in collaboration with the Bladder Cancer Advocacy Network, features an interprofessional expert panel that provides overview of the rationale and clinical evidence supporting the use of targeted, immunotherapeutic, and antibody-based strategies in bladder cancer. The panel also offers in-depth guidance on safe and effective integration of guideline-recommended therapies into personalized patient care and strategies to mitigate and manage adverse reactions and effectively support patients.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, oncologists, and other healthcare professionals involved in the care of patients with bladder cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize new evidence on therapeutic strategies for bladder cancer management based on innovative drug delivery approaches, modern immunotherapy regimens, and targeted agents across the disease continuum
• Develop educational strategies related to therapeutic expectations and safety considerations to enhance quality of life for patients with varying stages of bladder cancer
• Incorporate evidence- and team-based management and nursing protocols to address the unique suite of adverse events associated with approved and emerging therapeutics for bladder cancer

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Brenda Martone, MSN, ANP-BC, AOCNP
Adult Nurse Practitioner
Northwestern Medicine
Chicago, Illinois

Brenda Martone, MSN, ANP-BC, AOCNP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Archana Ajmera, MSN, ANP-BC, AOCNP
Adult Nurse Practitioner/Advanced Practice Provider Supervisor
University of California San Diego Moores Cancer Center
Division of Hematology Oncology
La Jolla, California

Archana Ajmera, MSN, ANP-BC, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bayer HealthCare Pharmaceuticals, Inc.; Eisai Co., Ltd.; Janssen Pharmaceuticals, Inc.; and Pfizer.

Faculty/Planner
Tian Zhang, MD, MHS
Associate Professor, Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Tian Zhang, MD, MHS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Aravive; AstraZeneca; AVEO Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Calithera Biosciences, Inc.; Eisai Co., Ltd.; Exelixis, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; Pharmacyclics LLC; QED Therapeutics; Sanofi; and Seagen Inc.
Grant/Research Support from Astellas Pharma Inc.; AstraZeneca; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Merrimack; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Tempus.
Other Financial or Material Support for leadership or fiduciary role in Kidney Cancer Association (KCA) Medical Steering Committee; Kidney Cancer Research Alliance (KCCure) Scientific Advisory Board; and National Cancer Institute (NCI) Steering Renal Task Force.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from Astellas and Seagen, AstraZeneca, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 1.25 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
1.25 points: Oncologic Emergencies, Oncology Nursing Practice, Professional Practice/Performance, Psychosocial Dimension of Care, Symptom Management, Palliative Care, Supportive Care, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/ILNA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 28, 2024; credit is no longer available.

Meeting Patient Needs Through Optimal Nursing Strategies in Personalized Bladder Cancer Care

Media: Enduring Material
Activity Release Date: April 29, 2023
Activity Expiration Date: May 28, 2024
Time to Complete Activity: 75 minutes

Activity Description

The therapeutic landscape for bladder cancer has rapidly evolved. The largely chemotherapy-based approaches of the past are giving way to the use of immune checkpoint inhibitors, targeted agents, and antibody–drug conjugates in advanced disease, as well as bladder-sparing and perioperative approaches in early-stage disease settings. How can oncology nurses synthesize the diverse body of clinical evidence on approved and emerging strategies into the realities of real-world cancer care to successfully address the therapeutic and educational needs of patients across the disease continuum?

To help nurses rise to the challenge of modern bladder cancer management, this PeerView activity, based on a recent live event and developed in collaboration with the Bladder Cancer Advocacy Network, features an interprofessional expert panel that provides overview of the rationale and clinical evidence supporting the use of targeted, immunotherapeutic, and antibody-based strategies in bladder cancer. The panel also offers in-depth guidance on safe and effective integration of guideline-recommended therapies into personalized patient care and strategies to mitigate and manage adverse reactions and effectively support patients.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, oncologists, and other healthcare professionals involved in the care of patients with bladder cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize new evidence on therapeutic strategies for bladder cancer management based on innovative drug delivery approaches, modern immunotherapy regimens, and targeted agents across the disease continuum
• Develop educational strategies related to therapeutic expectations and safety considerations to enhance quality of life for patients with varying stages of bladder cancer
• Incorporate evidence- and team-based management and nursing protocols to address the unique suite of adverse events associated with approved and emerging therapeutics for bladder cancer

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Brenda Martone, MSN, ANP-BC, AOCNP
Adult Nurse Practitioner
Northwestern Medicine
Chicago, Illinois

Brenda Martone, MSN, ANP-BC, AOCNP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Archana Ajmera, MSN, ANP-BC, AOCNP
Adult Nurse Practitioner/Advanced Practice Provider Supervisor
University of California San Diego Moores Cancer Center
Division of Hematology Oncology
La Jolla, California

Archana Ajmera, MSN, ANP-BC, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bayer HealthCare Pharmaceuticals, Inc.; Eisai Co., Ltd.; Janssen Pharmaceuticals, Inc.; and Pfizer.

Faculty/Planner
Tian Zhang, MD, MHS
Associate Professor, Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Tian Zhang, MD, MHS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Aravive; AstraZeneca; AVEO Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Calithera Biosciences, Inc.; Eisai Co., Ltd.; Exelixis, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; Pharmacyclics LLC; QED Therapeutics; Sanofi; and Seagen Inc.
Grant/Research Support from Astellas Pharma Inc.; AstraZeneca; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Merrimack; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Tempus.
Other Financial or Material Support for leadership or fiduciary role in Kidney Cancer Association (KCA) Medical Steering Committee; Kidney Cancer Research Alliance (KCCure) Scientific Advisory Board; and National Cancer Institute (NCI) Steering Renal Task Force.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from Astellas and Seagen, AstraZeneca, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 1.25 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
1.25 points: Oncologic Emergencies, Oncology Nursing Practice, Professional Practice/Performance, Psychosocial Dimension of Care, Symptom Management, Palliative Care, Supportive Care, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/ILNA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 27, 2024; credit is no longer available.

Nurses at the Forefront of the Continuing Success Story of Immunotherapy in NSCLC: Best Practices for Guiding and Supporting Patients Through Treatment and Survivorship

Media: Enduring Material
Activity Release Date: April 28, 2023
Activity Expiration Date: May 27, 2024
Time to Complete Activity: 90 minutes

Activity Description

In this activity based on a live MasterClass and Nursing Practice Forum, leading experts present concise learning modules combined with workshop-style demonstrations and case-based discussions to provide a practical framework for oncology nurses to facilitate optimal clinical integration of immunotherapies in advanced/metastatic and early-stage NSCLC, offering strategies to educate patients about this therapeutic class, mitigate acute and chronic immune-related adverse events (irAEs), and support patients through treatment and survivorship to help them achieve the best possible quality of life and outcomes.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, oncologists, and other clinicians involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the mechanisms of action, safety and efficacy, and current and emerging roles of immune checkpoint inhibitors (ICIs) and combinations in advanced- and early-stage NSCLC
• Collaborate with the interprofessional team to safely and effectively integrate ICI-based regimens into individualized treatment plans for eligible patients with advanced- and early-stage NSCLC
• Implement best practices for diagnosing and managing irAEs in patients with NSCLC receiving treatment with ICIs and combinations
• Provide education, guidance, and support to patients with NSCLC and their caregivers about ICI-based treatment options, importance of being vigilant about irAEs, and how to overcome challenges and optimize outcomes during treatment and survivorship

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Marianne Davies, DNP, ACNP, AOCNP, FAAN
Associate Professor
Yale School of Nursing
Oncology Nurse Practitioner
Yale Comprehensive Cancer Center & Smilow Cancer Center
New Haven, Connecticut

Marianne Davies, DNP, ACNP, AOCNP, FAAN, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Matthew A. Gubens, MD, MS
Associate Clinical Professor of Medicine
Medical Director, Thoracic Medical Oncology
Division of Hematology/Oncology
Department of Medicine
University of California San Francisco
San Francisco, California

Matthew A. Gubens, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; iTeos Therapeutics; Sanofi; Summit; and Surface.
Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.

Faculty/Planner
Elizabeth S. Waxman, BSN, MSN, APN-BC
Adult Nurse Practitioner
The University of Texas MD Anderson Cancer Center
Department of Thoracic/Head & Neck Medical Oncology
Houston, Texas

Elizabeth S. Waxman, BSN, MSN, APN-BC, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
1.5 points: Oncology Nursing Practice, Professional Practice/Performance, Roles of the APRN, Symptom Management, Palliative Care, Supportive Care, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/ILNA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 27, 2024; credit is no longer available.

Nurses at the Forefront of the Continuing Success Story of Immunotherapy in NSCLC: Best Practices for Guiding and Supporting Patients Through Treatment and Survivorship

Media: Enduring Material
Activity Release Date: April 28, 2023
Activity Expiration Date: May 27, 2024
Time to Complete Activity: 90 minutes

Activity Description

In this activity based on a live MasterClass and Nursing Practice Forum, leading experts present concise learning modules combined with workshop-style demonstrations and case-based discussions to provide a practical framework for oncology nurses to facilitate optimal clinical integration of immunotherapies in advanced/metastatic and early-stage NSCLC, offering strategies to educate patients about this therapeutic class, mitigate acute and chronic immune-related adverse events (irAEs), and support patients through treatment and survivorship to help them achieve the best possible quality of life and outcomes.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, oncologists, and other clinicians involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the mechanisms of action, safety and efficacy, and current and emerging roles of immune checkpoint inhibitors (ICIs) and combinations in advanced- and early-stage NSCLC
• Collaborate with the interprofessional team to safely and effectively integrate ICI-based regimens into individualized treatment plans for eligible patients with advanced- and early-stage NSCLC
• Implement best practices for diagnosing and managing irAEs in patients with NSCLC receiving treatment with ICIs and combinations
• Provide education, guidance, and support to patients with NSCLC and their caregivers about ICI-based treatment options, importance of being vigilant about irAEs, and how to overcome challenges and optimize outcomes during treatment and survivorship

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Marianne Davies, DNP, ACNP, AOCNP, FAAN
Associate Professor
Yale School of Nursing
Oncology Nurse Practitioner
Yale Comprehensive Cancer Center & Smilow Cancer Center
New Haven, Connecticut

Marianne Davies, DNP, ACNP, AOCNP, FAAN, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Matthew A. Gubens, MD, MS
Associate Clinical Professor of Medicine
Medical Director, Thoracic Medical Oncology
Division of Hematology/Oncology
Department of Medicine
University of California San Francisco
San Francisco, California

Matthew A. Gubens, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; iTeos Therapeutics; Sanofi; Summit; and Surface.
Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.

Faculty/Planner
Elizabeth S. Waxman, BSN, MSN, APN-BC
Adult Nurse Practitioner
The University of Texas MD Anderson Cancer Center
Department of Thoracic/Head & Neck Medical Oncology
Houston, Texas

Elizabeth S. Waxman, BSN, MSN, APN-BC, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
1.5 points: Oncology Nursing Practice, Professional Practice/Performance, Roles of the APRN, Symptom Management, Palliative Care, Supportive Care, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/ILNA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 25, 2024; credit is no longer available.

Expert Nursing Insights on Personalized Care for Gynecologic Cancers: Educating and Supporting Patients on the Latest Therapeutic Approaches

Media: Enduring Material
Activity Release Date: April 26, 2023
Activity Expiration Date: May 25, 2024
Time to Complete Activity: 90 minutes

Activity Description

As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process.

Target Audience

This activity has been designed to meet the educational needs of gynecologic and oncology nurses, NPs, PAs, and other healthcare professionals involved in the care of patients with gynecologic cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Review current efficacy and safety evidence of immunotherapy and PARP inhibitors in gynecologic malignancies such as endometrial, cervical, and ovarian cancers
• Implement nurse-guided strategies to integrate approved and emerging systemic therapy options into personalized management and education plans for patients with gynecologic cancers, including information on diagnostic testing, therapeutic expectations, safety considerations, and clinical trial opportunities
• Apply effective team-based safety strategies to promptly identify, mitigate, manage, and counsel patients on the spectrum of adverse events associated with systemic therapy for endometrial, cervical, and ovarian cancers

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Kimberly Halla, MSN, FNP-C
Family Nurse Practitioner
CaroMont Regional Medical Center
Gastonia, North Carolina

Kimberly Halla, MSN, FNP-C, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for SeaGen Inc.
Speaker for Eisai Inc.; GSK; Genmab A/S; and SeaGen Inc.

Faculty/Planner
Kimberly Camp, RN, MSN, ANP-BC, CNS, OCN
Gynecology Oncology Nurse Practitioner
Duke Women's Cancer Center
Division of Duke Gynecology/Oncology
Raleigh, North Carolina

Kimberly Camp, RN, MSN, ANP-BC, CNS, OCN, has a financial interest/relationship or affiliation in the form of:
Speaker for AstraZeneca; GSK; and Merck & Co., Inc.

Faculty/Planner
Kathleen N. Moore, MD, MS
Virginia Kerley Cade Chair in Developmental Therapeutics
Associate Director for Clinical Research
Director, Early Phase Drug Development
Stephenson Cancer Center at the University of Oklahoma HSC
Professor, Section of Gynecologic Oncology
Associate Program Director, Gynecologic Oncology Fellowship
Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alkmeres; Aravive; AstraZeneca; Blueprint Medicines Corporation; Caris Life Sciences; Clovis Oncology; Eisai Inc.; Elevar Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline/Tesaro, Inc.; I-Mab Biopharma Co., Ltd.; Immunogen; InxMed; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetic, Inc.; Novartis Pharmaceuticals Corporation; Onconova Therapeutics; OncXerna Therapeutics, Inc.; Tarveda Therapeutics; The GOG Foundation Inc.; VBL Therapeutics; and Verastem, Inc.
Grant/Research Support from GlaxoSmithKline/Tesaro, Inc.; Lilly; Merck & Co., Inc.; PTC Therapeutics; and Verastem, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported by educational grants from Eisai Inc., GSK, Merck & Co., Inc., and Novocure, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:


The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/ILNA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 25, 2024; credit is no longer available.

Expert Nursing Insights on Personalized Care for Gynecologic Cancers: Educating and Supporting Patients on the Latest Therapeutic Approaches

Media: Enduring Material
Activity Release Date: April 26, 2023
Activity Expiration Date: May 25, 2024
Time to Complete Activity: 90 minutes

Activity Description

As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process.

Target Audience

This activity has been designed to meet the educational needs of gynecologic and oncology nurses, NPs, PAs, and other healthcare professionals involved in the care of patients with gynecologic cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Review current efficacy and safety evidence of immunotherapy and PARP inhibitors in gynecologic malignancies such as endometrial, cervical, and ovarian cancers
• Implement nurse-guided strategies to integrate approved and emerging systemic therapy options into personalized management and education plans for patients with gynecologic cancers, including information on diagnostic testing, therapeutic expectations, safety considerations, and clinical trial opportunities
• Apply effective team-based safety strategies to promptly identify, mitigate, manage, and counsel patients on the spectrum of adverse events associated with systemic therapy for endometrial, cervical, and ovarian cancers

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Kimberly Halla, MSN, FNP-C
Family Nurse Practitioner
CaroMont Regional Medical Center
Gastonia, North Carolina

Kimberly Halla, MSN, FNP-C, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for SeaGen Inc.
Speaker for Eisai Inc.; GSK; Genmab A/S; and SeaGen Inc.

Faculty/Planner
Kimberly Camp, RN, MSN, ANP-BC, CNS, OCN
Gynecology Oncology Nurse Practitioner
Duke Women's Cancer Center
Division of Duke Gynecology/Oncology
Raleigh, North Carolina

Kimberly Camp, RN, MSN, ANP-BC, CNS, OCN, has a financial interest/relationship or affiliation in the form of:
Speaker for AstraZeneca; GSK; and Merck & Co., Inc.

Faculty/Planner
Kathleen N. Moore, MD, MS
Virginia Kerley Cade Chair in Developmental Therapeutics
Associate Director for Clinical Research
Director, Early Phase Drug Development
Stephenson Cancer Center at the University of Oklahoma HSC
Professor, Section of Gynecologic Oncology
Associate Program Director, Gynecologic Oncology Fellowship
Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alkmeres; Aravive; AstraZeneca; Blueprint Medicines Corporation; Caris Life Sciences; Clovis Oncology; Eisai Inc.; Elevar Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline/Tesaro, Inc.; I-Mab Biopharma Co., Ltd.; Immunogen; InxMed; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetic, Inc.; Novartis Pharmaceuticals Corporation; Onconova Therapeutics; OncXerna Therapeutics, Inc.; Tarveda Therapeutics; The GOG Foundation Inc.; VBL Therapeutics; and Verastem, Inc.
Grant/Research Support from GlaxoSmithKline/Tesaro, Inc.; Lilly; Merck & Co., Inc.; PTC Therapeutics; and Verastem, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported by educational grants from Eisai Inc., GSK, Merck & Co., Inc., and Novocure, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:


The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/ILNA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 17, 2024; credit is no longer available.

Addressing Unmet Nursing Needs in the Management of IBS-C: Understanding the Mechanism of Disease, Newer Therapies, and Coordinated Approaches to Treatment Barriers

Activity Description and Educational Objectives

Patients with irritable bowel syndrome with constipation (IBS-C) are often more comfortable discussing their concerns with the nurses on their healthcare team, which demonstrates the need for team-based care in order to maximize management, enhance outcomes, and improve quality of life. This activity features an expert overview of the pathophysiology of IBS-C and targets for therapy, including novel NHE3 inhibitors, as well as evidence-based treatment approaches with a focus on identifying and overcoming barriers to guideline-based care. Hear about recent advances in the diagnosis and treatment of IBS-C, specifically the mechanisms of the condition, current and emerging therapies, and coordinated approaches for overcoming barriers to care.

Upon completion of this activity, participants should be better able to:

• Describe the pathophysiology and potential therapeutic targets for IBS-C
• Use patient-centered tactics and tools to overcome barriers to guideline-directed IBS-C management
• Create team-based approaches to IBS-C management in accordance with current evidence and guidelines, recognizing the appropriate use of current and emerging therapeutic agents

Target Audience

This activity has been designed to meet the educational needs of gastroenterology nurses and other healthcare professionals involved in the care of patients with irritable bowel syndrome with constipation (IBS-C).

Requirements for Successful Completion

Successful completion of this accredited continuing education activity is based on:

• Being registered for this activity
• Viewing the program in its entirety
• Completion of the post-test
• Completion of the evaluation

Media: Enduring Material
Release and Expiration Dates: April 18, 2023 - May 17, 2024
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

Per the disclosure policy of the Society of Gastroenterology Nurses and Associates, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any ineligible companies related to this activity. These relationships are mitigated and materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

Co-Chairs & Presenters
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Ardelyx; QOL Medical, LLC; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Speaker for AbbVie Inc.; Ardelyx; QOL Medical, LLC; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Kimberly Kearns, APRN, ANP-BC
DULY Gastroenterology Department
DULY Health and Care
Hoffman Estates, Illinois

Kimberly Kearns, APRN, ANP-BC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ardelyx; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer; and Salix Pharmaceuticals.
Speakers Bureau participant with Janssen Pharmaceuticals, Inc.; Lilly; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Society of Gastroenterology Nurses and Associates (SGNA) staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships. All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

The Society of Gastroenterology Nurses and Associates, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Upon successful completion of this accredited continuing education activity, participants will be awarded 1.0 contact hours.

Support

This activity is supported by an educational grant from Ardelyx.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, and Society of Gastroenterology Nurses and Associates (SGNA) are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Society of Gastroenterology Nurses and Associates (SGNA). The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 17, 2024; credit is no longer available.

Addressing Unmet Nursing Needs in the Management of IBS-C: Understanding the Mechanism of Disease, Newer Therapies, and Coordinated Approaches to Treatment Barriers

Activity Description and Educational Objectives

Patients with irritable bowel syndrome with constipation (IBS-C) are often more comfortable discussing their concerns with the nurses on their healthcare team, which demonstrates the need for team-based care in order to maximize management, enhance outcomes, and improve quality of life. This activity features an expert overview of the pathophysiology of IBS-C and targets for therapy, including novel NHE3 inhibitors, as well as evidence-based treatment approaches with a focus on identifying and overcoming barriers to guideline-based care. Hear about recent advances in the diagnosis and treatment of IBS-C, specifically the mechanisms of the condition, current and emerging therapies, and coordinated approaches for overcoming barriers to care.

Upon completion of this activity, participants should be better able to:

• Describe the pathophysiology and potential therapeutic targets for IBS-C
• Use patient-centered tactics and tools to overcome barriers to guideline-directed IBS-C management
• Create team-based approaches to IBS-C management in accordance with current evidence and guidelines, recognizing the appropriate use of current and emerging therapeutic agents

Target Audience

This activity has been designed to meet the educational needs of gastroenterology nurses and other healthcare professionals involved in the care of patients with irritable bowel syndrome with constipation (IBS-C).

Requirements for Successful Completion

Successful completion of this accredited continuing education activity is based on:

• Being registered for this activity
• Viewing the program in its entirety
• Completion of the post-test
• Completion of the evaluation

Media: Enduring Material
Release and Expiration Dates: April 18, 2023 - May 17, 2024
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

Per the disclosure policy of the Society of Gastroenterology Nurses and Associates, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any ineligible companies related to this activity. These relationships are mitigated and materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

Co-Chairs & Presenters
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Ardelyx; QOL Medical, LLC; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Speaker for AbbVie Inc.; Ardelyx; QOL Medical, LLC; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Kimberly Kearns, APRN, ANP-BC
DULY Gastroenterology Department
DULY Health and Care
Hoffman Estates, Illinois

Kimberly Kearns, APRN, ANP-BC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ardelyx; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer; and Salix Pharmaceuticals.
Speakers Bureau participant with Janssen Pharmaceuticals, Inc.; Lilly; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Society of Gastroenterology Nurses and Associates (SGNA) staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships. All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

The Society of Gastroenterology Nurses and Associates, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Upon successful completion of this accredited continuing education activity, participants will be awarded 1.0 contact hours.

Support

This activity is supported by an educational grant from Ardelyx.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, and Society of Gastroenterology Nurses and Associates (SGNA) are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Society of Gastroenterology Nurses and Associates (SGNA). The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on April 29, 2024; credit is no longer available.

Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

Media: Enduring Material
Activity Release Date: March 31, 2023
Activity Expiration Date: April 29, 2024
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment mix in CLL!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other clinicians involved in the management of CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize the mechanistic and pharmacokinetic profiles, and safety/efficacy evidence supporting the treatment roles of novel BTK and BCL-2 inhibitor approaches in CLL
• Develop pharmacy-guided plans to optimize the integration of novel and emerging BTK and BCL-2 inhibitor strategies into personalized management plans for patients with TN and RR CLL
• Work collaboratively to address practical aspects of team-based care with targeted therapies in CLL, including care coordination, drug-drug interactions, patient counseling, staff education, and safety and dosing considerations

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Emily K. Dotson, PharmD, BCOP
Inpatient Clinical Manager
Clinical Pharmacist Specialist - Hematology
The James Cancer Hospital
Columbus, Ohio

Emily K. Dotson, PharmD, BCOP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; and Janssen Pharmaceuticals, Inc.

Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
Program Director, PGY2 Oncology Pharmacy Residency
NewYork-Presbyterian Hospital
New York, New York

Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Sarah E. Stump, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist – Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, Tennessee

Sarah E. Stump, PharmD, BCPS, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-012-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on April 29, 2024; credit is no longer available.

Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

Media: Enduring Material
Activity Release Date: March 31, 2023
Activity Expiration Date: April 29, 2024
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment mix in CLL!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other clinicians involved in the management of CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize the mechanistic and pharmacokinetic profiles, and safety/efficacy evidence supporting the treatment roles of novel BTK and BCL-2 inhibitor approaches in CLL
• Develop pharmacy-guided plans to optimize the integration of novel and emerging BTK and BCL-2 inhibitor strategies into personalized management plans for patients with TN and RR CLL
• Work collaboratively to address practical aspects of team-based care with targeted therapies in CLL, including care coordination, drug-drug interactions, patient counseling, staff education, and safety and dosing considerations

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Emily K. Dotson, PharmD, BCOP
Inpatient Clinical Manager
Clinical Pharmacist Specialist - Hematology
The James Cancer Hospital
Columbus, Ohio

Emily K. Dotson, PharmD, BCOP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; and Janssen Pharmaceuticals, Inc.

Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
Program Director, PGY2 Oncology Pharmacy Residency
NewYork-Presbyterian Hospital
New York, New York

Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Sarah E. Stump, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist – Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, Tennessee

Sarah E. Stump, PharmD, BCPS, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-012-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on April 15, 2024; credit is no longer available.

Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact Treatment Decisions for Your Patients?

Media: Enduring Material
Activity Release Date: March 2, 2023
Activity Expiration Date: April 15, 2024
Time to Complete Activity: 60 minutes

Activity Description

Late-onset Alzheimer’s disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA).

In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families.

Target Audience

This activity has been designed to meet the educational needs of healthcare professionals involved in the interdisciplinary and interprofessional diagnosis and care of patients with or at risk for Alzheimer’s disease (AD), including neurologists, psychiatrists, geneticists, family and internal medicine physicians, advanced practice clinicians, psychologists, pharmacists, social workers, and genetic counselors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care
• Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting
• Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients’ needs in consultation with other members of the healthcare team

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert C. Green, MD, MPH
Professor of Medicine (Genetics)
Mass General Brigham
Harvard Medical School
Boston, Massachusetts

Robert C. Green, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AIA; Allelica, Inc.; Atria; Fabric; Genome Web; Genomic Life; GRAIL, Inc.; Verily Life Sciences LLC; and VinBigData.
Other Financial or Material Support as Co-Founder of Genome Medical and Nurture Genomics.

Faculty/Planner
Liana G. Apostolova, MS, MD, FAAN
Distinguished Professor in Neurology
Barbara and Peer Baekgaard Chair in Alzheimer’s Disease Research
Professor of Radiology and Medical and Molecular Genetics
Indiana University School of Medicine
Indiana Alzheimer's Disease Center
Indianapolis, Indiana

Liana G. Apostolova, MS, MD, FAAN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Florida Department of Health; Food and Drug Administration (FDA); GE Healthcare; Genentech, Inc.; IQVIA Inc.; Lilly; New Mexico Exploratory ADRC; TwoLabs, LLC; and UAB Nathan Schock Center.
Grant/Research Support from AVID Pharmaceuticals; F. Hoffmann-La Roche Ltd; Life Molecular Imaging; and Lilly.

Faculty/Planner
Stephen P. Salloway, MD, MS
Martin M. Zucker Professor of Psychiatry and Human Behavior
Professor of Neurology
Alpert Medical School of Brown University
Associate Director
Brown Center for Alzheimer’s Disease Research
Providence, Rhode Island

Stephen P. Salloway, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acumen Pharmaceuticals, Inc.; Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Lilly; Novo Nordisk Inc.; and Prothena Corporation plc.
Grant/Research Support from Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-017-H01-P
Type of Activity: Application

Social Workers

As a Jointly Accredited Organization, PVI, PeerView Institute for Medical Education, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1 general continuing education credits.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/ASWB-ACE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on April 15, 2024; credit is no longer available.

Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact Treatment Decisions for Your Patients?

Media: Enduring Material
Activity Release Date: March 2, 2023
Activity Expiration Date: April 15, 2024
Time to Complete Activity: 60 minutes

Activity Description

Late-onset Alzheimer’s disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA).

In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families.

Target Audience

This activity has been designed to meet the educational needs of healthcare professionals involved in the interdisciplinary and interprofessional diagnosis and care of patients with or at risk for Alzheimer’s disease (AD), including neurologists, psychiatrists, geneticists, family and internal medicine physicians, advanced practice clinicians, psychologists, pharmacists, social workers, and genetic counselors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care
• Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting
• Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients’ needs in consultation with other members of the healthcare team

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert C. Green, MD, MPH
Professor of Medicine (Genetics)
Mass General Brigham
Harvard Medical School
Boston, Massachusetts

Robert C. Green, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AIA; Allelica, Inc.; Atria; Fabric; Genome Web; Genomic Life; GRAIL, Inc.; Verily Life Sciences LLC; and VinBigData.
Other Financial or Material Support as Co-Founder of Genome Medical and Nurture Genomics.

Faculty/Planner
Liana G. Apostolova, MS, MD, FAAN
Distinguished Professor in Neurology
Barbara and Peer Baekgaard Chair in Alzheimer’s Disease Research
Professor of Radiology and Medical and Molecular Genetics
Indiana University School of Medicine
Indiana Alzheimer's Disease Center
Indianapolis, Indiana

Liana G. Apostolova, MS, MD, FAAN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Florida Department of Health; Food and Drug Administration (FDA); GE Healthcare; Genentech, Inc.; IQVIA Inc.; Lilly; New Mexico Exploratory ADRC; TwoLabs, LLC; and UAB Nathan Schock Center.
Grant/Research Support from AVID Pharmaceuticals; F. Hoffmann-La Roche Ltd; Life Molecular Imaging; and Lilly.

Faculty/Planner
Stephen P. Salloway, MD, MS
Martin M. Zucker Professor of Psychiatry and Human Behavior
Professor of Neurology
Alpert Medical School of Brown University
Associate Director
Brown Center for Alzheimer’s Disease Research
Providence, Rhode Island

Stephen P. Salloway, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acumen Pharmaceuticals, Inc.; Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Lilly; Novo Nordisk Inc.; and Prothena Corporation plc.
Grant/Research Support from Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-017-H01-P
Type of Activity: Application

Social Workers

As a Jointly Accredited Organization, PVI, PeerView Institute for Medical Education, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1 general continuing education credits.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/ASWB-ACE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on February 20, 2024; credit is no longer available.

What's New in the Management of Eosinophilic Esophagitis: Working Together to Integrate Targeted Treatment Options Into Practice

Media: Enduring Material
Activity Release Date: February 21, 2023
Activity Expiration Date: February 20, 2024
Time to Complete Activity: 30 minutes

Activity Description

Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. Diagnosis of EoE is frequently missed or delayed, which can lead to such complications as esophageal stricture and reduced patient quality of life.

Fortunately, targeted biologic therapies already approved for other type 2 inflammatory disorders are approved, or are in development, for the treatment of EoE and appear promising.

This case-based activity will offer expert insights for recognizing and diagnosing EoE, monitoring and managing EoE, and integrating targeted therapies into practice.

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, specialty NPs and PAs, and other healthcare professionals involved in the care of patients with EoE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Diagnose eosinophilic esophagitis (EoE) promptly according to the latest guidelines and criteria to decrease the risk of complications precipitated by uncontrolled disease
• Apply the latest clinical research developments and updates in treatment guidelines to the management of EoE in collaboration with the healthcare team
• Select treatment, including novel targeted biologic therapies, for patients with EoE based on the latest clinical evidence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Evan S. Dellon, MD, MPH
Professor of Medicine and Adjunct Professor of Epidemiology
Director, UNC Center for Esophageal Diseases and Swallowing (CEDAS)
Division of Gastroenterology and Hepatology
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Evan S. Dellon, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; AbbVie Inc.; Adare Pharma Solutions/Ellodi Pharmaceuticals; Aimmune Therapeutics; Akesa Pharma Pty Ltd; Alfasigma S.p.A.; ALK; Allakos Inc.; Amgen Inc.; Arena Pharmaceuticals; ASLAN; AstraZeneca; Avir Pharma; Biorasi, LLC; Calypso Biotech; Celgene Corporation/Receptos/Bristol Myers Squibb; Celldex Therapeutics; EsoCap AG; Eupraxia Pharmaceuticals; Ferring B.V.; GSK; Gossamer Bio; Holoclara; Invea Therapeutics, Inc.; Landos Biopharma, Inc.; Lilly; Lucid Diagnostics; Morphic Therapeutic, Inc.; Nexstone Immunology; Nutricia; Parexel International Corporation/Calyx Chemicals & Pharmaceuticals Ltd.; Phathom Pharmaceuticals; Regeneron Pharmaceuticals Inc.; Revolo Biotherapeutics; Robarts/Alimentiv (US) Inc.; Salix Pharmaceuticals; Sanofi; Shire/Takeda Pharmaceuticals U.S.A., Inc.; Target RWE; and Upstream Bio, Inc.
Grant/Research Support from Adare Pharma Solutions/Ellodi Pharmaceuticals; Allakos Inc.; Arena Pharmaceuticals; AstraZeneca; Celgene Corporation/Receptos/Bristol Myers Squibb; GSK; Meritage Pharma, Inc.; Miraca; Nutricia; Regeneron Pharmaceuticals Inc.; Revolo Biotherapeutics; and Shire/Takeda Pharmaceuticals U.S.A., Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on February 20, 2024; credit is no longer available.

What's New in the Management of Eosinophilic Esophagitis: Working Together to Integrate Targeted Treatment Options Into Practice

Media: Enduring Material
Activity Release Date: February 21, 2023
Activity Expiration Date: February 20, 2024
Time to Complete Activity: 30 minutes

Activity Description

Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. Diagnosis of EoE is frequently missed or delayed, which can lead to such complications as esophageal stricture and reduced patient quality of life.

Fortunately, targeted biologic therapies already approved for other type 2 inflammatory disorders are approved, or are in development, for the treatment of EoE and appear promising.

This case-based activity will offer expert insights for recognizing and diagnosing EoE, monitoring and managing EoE, and integrating targeted therapies into practice.

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, specialty NPs and PAs, and other healthcare professionals involved in the care of patients with EoE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Diagnose eosinophilic esophagitis (EoE) promptly according to the latest guidelines and criteria to decrease the risk of complications precipitated by uncontrolled disease
• Apply the latest clinical research developments and updates in treatment guidelines to the management of EoE in collaboration with the healthcare team
• Select treatment, including novel targeted biologic therapies, for patients with EoE based on the latest clinical evidence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Evan S. Dellon, MD, MPH
Professor of Medicine and Adjunct Professor of Epidemiology
Director, UNC Center for Esophageal Diseases and Swallowing (CEDAS)
Division of Gastroenterology and Hepatology
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Evan S. Dellon, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; AbbVie Inc.; Adare Pharma Solutions/Ellodi Pharmaceuticals; Aimmune Therapeutics; Akesa Pharma Pty Ltd; Alfasigma S.p.A.; ALK; Allakos Inc.; Amgen Inc.; Arena Pharmaceuticals; ASLAN; AstraZeneca; Avir Pharma; Biorasi, LLC; Calypso Biotech; Celgene Corporation/Receptos/Bristol Myers Squibb; Celldex Therapeutics; EsoCap AG; Eupraxia Pharmaceuticals; Ferring B.V.; GSK; Gossamer Bio; Holoclara; Invea Therapeutics, Inc.; Landos Biopharma, Inc.; Lilly; Lucid Diagnostics; Morphic Therapeutic, Inc.; Nexstone Immunology; Nutricia; Parexel International Corporation/Calyx Chemicals & Pharmaceuticals Ltd.; Phathom Pharmaceuticals; Regeneron Pharmaceuticals Inc.; Revolo Biotherapeutics; Robarts/Alimentiv (US) Inc.; Salix Pharmaceuticals; Sanofi; Shire/Takeda Pharmaceuticals U.S.A., Inc.; Target RWE; and Upstream Bio, Inc.
Grant/Research Support from Adare Pharma Solutions/Ellodi Pharmaceuticals; Allakos Inc.; Arena Pharmaceuticals; AstraZeneca; Celgene Corporation/Receptos/Bristol Myers Squibb; GSK; Meritage Pharma, Inc.; Miraca; Nutricia; Regeneron Pharmaceuticals Inc.; Revolo Biotherapeutics; and Shire/Takeda Pharmaceuticals U.S.A., Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on January 30, 2024; credit is no longer available.

Building a Safety-Centric Culture in B-Cell Cancers: Interprofessional Insights on Optimizing BTKi Efficacy Through Safety Management

Media: Enduring Material
Activity Release Date: January 31, 2023
Activity Expiration Date: January 30, 2024
Time to Complete Activity: 60 minutes

Activity Description

BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematology-oncology nurses, pharmacists, cardiologists, and other clinicians involved in the care of patients with B-cell malignancies.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues
• Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection
• Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
New York, New York

Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Christina Russomanno, RN, MS, NP-C
Nurse Practitioner, Leukemia Service
Director of Nursing, Outpatient Hematology/Oncology
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

Christina Russomanno, RN, MS, NP-C, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-010-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on January 30, 2024; credit is no longer available.

Building a Safety-Centric Culture in B-Cell Cancers: Interprofessional Insights on Optimizing BTKi Efficacy Through Safety Management

Media: Enduring Material
Activity Release Date: January 31, 2023
Activity Expiration Date: January 30, 2024
Time to Complete Activity: 60 minutes

Activity Description

BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematology-oncology nurses, pharmacists, cardiologists, and other clinicians involved in the care of patients with B-cell malignancies.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues
• Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection
• Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
New York, New York

Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Christina Russomanno, RN, MS, NP-C
Nurse Practitioner, Leukemia Service
Director of Nursing, Outpatient Hematology/Oncology
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

Christina Russomanno, RN, MS, NP-C, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-010-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView